RxDoctor Payments Data

Casie Smith, NP

Nurse Practitioner · Chapin, SCNPI 1811367071

Payments from drug & device makers

$732in general payments, 2019–2025

Across 29 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$209
  • Sun Pharmaceutical Industries Inc.$169
  • Lilly USA, LLC$138
  • Viatris Specialty LLC$73
  • Neurocrine Biosciences, Inc.$60
  • Mylan Specialty L.p.$55
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$732 in reported general payments places this provider in the 75th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$133,764
Medicare patients
219
Services billed
1,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$88,529
EliquisApixaban55$20,142
Lacosamide13$9,591
ErtapenemErtapenem Sodium13$6,791
XareltoRivaroxaban21$6,551
MyrbetriqMirabegron21$5,025
Sucralfate52$4,507
Pantoprazole Sodium47$3,375
Divalproex Sodium32$3,292
Budesonide14$2,359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$1,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$1,657
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate54$1,648
Atorvastatin Calcium104$1,600
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$60$88,52925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Chapin

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →